Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Second-wave direct-acting antivirals for hepatitis C: Sofosbuvir and Ledipasvir. Lansdale: HAYES, Inc.. Directory Publication. 2014 Authors' objectives The second-wave direct-acting antivirals (DAAs) are prescribed to treat chronic hepatitis C with the objective of achieving sustained viral response and preventing harmful liver damage. These agents were developed to address the issues associated with pegylated interferon, ribavirin, and previously approved DAAs, including lack of response and relapse, resistance, poor safety profile, and burdensome treatment regimen. Second-wave DAA agents include simeprevir, sofosbuvir, and the combination of sofosbuvir and ledipasvir. Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Indexing Status Subject indexing assigned by CRD MeSH Antiviral Agents; Hepatitis C, Chronic; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32014001198 Date abstract record published 29/10/2014 |